FA
REGN icon

Fagan Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Fagan Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7M Sell
13,912
-19
-0.1% -$14.5K 1.49% 19
2025
Q4 		$10.8M Sell
13,931
-47
-0.3% -$31.9K 1.43% 23
2025
Q3 		$7.86M Buy
13,978
+138
+1% +$78K 1.09% 28
2025
Q2 		$7.27M Buy
13,840
+714
+5% +$399K 1.12% 30
2025
Q1 		$8.33M Buy
13,126
+203
+2% +$140K 1.39% 22
2024
Q4 		$9.21M Buy
12,923
+3,832
+42% +$3.22M 1.46% 18
2024
Q3 		$9.56M Buy
9,091
+28
+0.3% +$31.2K 1.61% 16
2024
Q2 		$9.53M Buy
9,063
+119
+1% +$115K 1.67% 15
2024
Q1 		$8.61M Buy
8,944
+216
+2% +$205K 1.61% 17
2023
Q4 		$7.67M Buy
8,728
+91
+1% +$74.9K 1.67% 19
2023
Q3 		$7.11M Buy
8,637
+354
+4% +$278K 1.72% 20
2023
Q2 		$5.95M Buy
8,283
+145
+2% +$112K 1.44% 22
2023
Q1 		$6.69M Buy
8,138
+178
+2% +$134K 1.66% 20
2022
Q4 		$5.74M Sell
7,960
-131
-2% -$96.7K 1.53% 23
2022
Q3 		$5.57M Sell
8,091
-40
-0.5% -$25.2K 1.56% 21
2022
Q2 		$4.81M Sell
8,131
-3
-0% -$1.95K 1.28% 26
2022
Q1 		$5.68M Buy
8,134
+192
+2% +$121K 1.17% 29
2021
Q4 		$5.02M Buy
7,942
+225
+3% +$138K 0.95% 28
2021
Q3 		$4.67M Buy
7,717
+4
+0.1% +$2.48K 1.01% 29
2021
Q2 		$4.31M Buy
7,713
+244
+3% +$124K 0.92% 34
2021
Q1 		$3.53M Buy
7,469
+702
+10% +$342K 0.83% 37
2020
Q4 		$3.27M Buy
6,767
+486
+8% +$262K 0.82% 37
2020
Q3 		$3.52M Buy
6,281
+578
+10% +$350K 1.01% 29
2020
Q2 		$3.56M Sell
5,703
-41
-0.7% -$23.3K 1.13% 27
2020
Q1 		$2.81M Buy
5,744
+5,187
+931% +$2.14M 1.11% 26
2019
Q4 		$209K Buy
+557
New +$187K 0.07% 114
2019
Q2 		– Sell
-550
Closed -$2.26M – 116
2019
Q1 		$2.26M Hold
550
– – 0.97% 30
2018
Q4 		$205K Hold
550
– – 0.11% 103
2018
Q3 		$222K Sell
550
-55
-9% -$20.9K 0.09% 112
2018
Q2 		$209K Hold
605
– – 0.09% 109
2018
Q1 		$208 Hold
605
– – 0.09% 100
2017
Q4 		$227 Sell
605
-2,713
-82% -$1.1M 0.09% 101
2017
Q3 		$1.48M Buy
3,318
+203
+7% +$96.6K 0.73% 44
2017
Q2 		$1.53M Buy
3,115
+226
+8% +$98.9K 0.8% 40
2017
Q1 		$1.12M Buy
2,889
+54
+2% +$20K 0.62% 50
2016
Q4 		$1.04M Buy
2,835
+1,070
+61% +$407K 0.6% 49
2016
Q3 		$710K Buy
1,765
+945
+115% +$379K 0.43% 58
2016
Q2 		$286K Buy
820
+20
+3% +$7.7K 0.18% 83
2016
Q1 		$288K Sell
800
-10
-1% -$4.12K 0.19% 81
2015
Q4 		$440K Buy
810
+75
+10% +$40.6K 0.29% 68
2015
Q3 		$342K Buy
735
+15
+2% +$8.05K 0.25% 76
2015
Q2 		$367K Sell
720
-15
-2% -$7.32K 0.24% 77
2015
Q1 		$332K Sell
735
-135
-16% -$57.2K 0.25% 79
2014
Q4 		$357K Hold
870
– – 0.28% 71
2014
Q3 		$314K Hold
870
– – 0.26% 76
2014
Q2 		$246K Buy
870
+35
+4% +$10.4K 0.21% 79
2014
Q1 		$251K Buy
+835
New +$257K 0.22% 80

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fagan Associates's REGN Position: Q1 2026 in Review

Fagan Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 0.14% in Q1 2026, selling an estimated $14.5K and leaving 13,912 shares worth $10.7M. The position accounts for 1.49% of the portfolio, ranked #19.

Fagan Associates first reported a position in REGN in Q1 2014 and has held it in 47 quarters since. The position peaked at $10.8M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Fagan Associates held 13,912 shares of Regeneron Pharmaceuticals worth $10.7M as of Q1 2026.
  • Fagan Associates sold 19 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $14.5K.
  • Regeneron Pharmaceuticals made up 1.49% of Fagan Associates's portfolio in Q1 2026, its #19 holding.
  • Fagan Associates first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 47 quarters since.
  • Fagan Associates's Regeneron Pharmaceuticals position peaked at $10.8M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Fagan Associates's 13F filing for Q1 2026, filed 4 May 2026.